Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.61 |
| ▸ | TP53 | P04637 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | EDNRB | P24530 | 2/20 | 0.55 |
| ▸ | EDNRA | P25101 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | YWHAH | Q04917 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952730 | 0.84 | MAPT (0.62) | PLA2G10PLA2G2ATP53MAPTEDNRB | |
| SCHEMBL17625299 | 0.81 | FOLH1 (0.62) | — | |
| SCHEMBL13764925 | 0.79 | PLA2G10 (0.56) | PLA2G10PLA2G2APLA2G1BCNR2MTNR1A | |
| SCHEMBL2552008 | 0.78 | TP53 (0.60) | TP53MAPTYWHAH | |
| SCHEMBL2555312 | 0.78 | TP53 (0.59) | TP53MAPTYWHAH | |
| SCHEMBL7963220 | 0.78 | PLA2G10 (1.00) | PLA2G10PLA2G2APLA2G1B | |
| SCHEMBL3726839 | 0.77 | S1PR3 (0.67) | PLA2G10PLA2G2ACNR2 | |
| SCHEMBL2272636 | 0.77 | KDM4E (0.49) | MAPT | |
| SCHEMBL3471153 | 0.77 | KMT2A (0.68) | PLA2G10PLA2G2APLA2G1BCNR2MTNR1A | |
| SCHEMBL7963970 | 0.76 | PLA2G2A (1.00) | PLA2G10PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | PLA2G10 217/4885PLA2G2A 114/4885TP53 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.